The death domain kinase RIP protects thymocytes from tumor necrosis factor receptor type 2-induced cell death
Authors
Hermance, Nicole M.Oikemus, Sarah R.
Kilpatrick, Elizabeth D.
Cunningham, Leslie A.
Kelliher, Michelle
UMass Chan Affiliations
Department of Cancer BiologyDepartment of Molecular Genetics and Microbiology
Graduate School of Biomedical Sciences
Document Type
Journal ArticlePublication Date
2002-07-03Keywords
Animals; Antigens, CD; Apoptosis; Cell Differentiation; Cell Survival; Flow Cytometry; Gene Targeting; Hematopoietic Stem Cell Transplantation; Heterozygote; Homozygote; Liver; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; NF-kappa B; Proteins; Radiation Chimera; Receptor-Interacting Protein Serine-Threonine Kinases; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; T-Lymphocytes; Thymus GlandLife Sciences
Medicine and Health Sciences
Metadata
Show full item recordAbstract
Fas and the tumor necrosis factor receptor (TNFR)1 regulate the programmed cell death of lymphocytes. The death domain kinase, receptor interacting protein (rip), is recruited to the TNFR1 upon receptor activation. In vitro, rip-/- fibroblasts are sensitive to TNF-induced cell death due to an impaired nuclear factor kappaB response. Because rip-/- mice die at birth, we were unable to examine the effects of a targeted rip mutation on lymphocyte survival. To address the contribution of RIP to immune homeostasis, we examined lethally irradiated mice reconstituted with rip-/- hematopoietic precursors. We observed a decrease in rip-/- thymocytes and T cells in both wild-type C57BL/6 and recombination activating gene 1-/- irradiated hosts. In contrast, the B cell and myeloid lineages are unaffected by the absence of rip. Thus, the death domain kinase rip is required for T cell development. Unlike Fas-associated death domain, rip does not regulate T cell proliferation, as rip-/- T cells respond to polyclonal activators. However, rip-deficient mice contain few viable CD4+ and CD8+ thymocytes, and rip-/- thymocytes are sensitive to TNF-induced cell death. Surprisingly, the rip-associated thymocyte apoptosis was not rescued by the absence of TNFR1, but appears to be rescued by an absence of TNFR2. Taken together, this study implicates RIP and TNFR2 in thymocyte survival.Source
J Exp Med. 2002 Jul 1;196(1):15-26.
DOI
10.1084/jem.20011470Permanent Link to this Item
http://hdl.handle.net/20.500.14038/33588PubMed ID
12093867Related Resources
ae974a485f413a2113503eed53cd6c53
10.1084/jem.20011470
Scopus Count
Related items
Showing items related by title, author, creator and subject.
-
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorptionGravallese, Ellen M.; Galson, Deborah L.; Goldring, Steven R.; Auron, Philip E. (2001-02-15)The contribution of osteoclasts to the process of bone loss in inflammatory arthritis has recently been demonstrated. Studies in osteoclast biology have led to the identification of factors responsible for the differentiation and activation of osteoclasts, the most important of which is the receptor activator of NF-kappa B ligand/osteoclast differentiation factor (RANKL/ODF), a tumor necrosis factor (TNF)-like protein. The RANKL/ODF receptor, receptor activator of NF-kappa B (RANK), is a TNF-receptor family member present on both osteoclast precursors and mature osteoclasts. Like other TNF-family receptors and the IL-1 receptor, RANK mediates its signal transduction via TNF receptor-associated factor (TRAF) proteins, suggesting that the signaling pathways activated by RANK and other inflammatory cytokines involved in osteoclast differentiation and activation are interconnected. -
Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transductionFitzgerald, Katherine A.; Palsson-McDermott, Eva M.; Bowie, Andrew G.; Jefferies, Caroline A.; Mansell, Ashley S.; Brady, Gerard; Brint, Elizabeth K.; Dunne, Aisling; Gray, Pearl; Harte, Mary T.; et al. (2001-09-07)The recognition of microbial pathogens by the innate immune system involves Toll-like receptors (TLRs), which recognize pathogen-associated molecular patterns. Different TLRs recognize different pathogen-associated molecular patterns, with TLR-4 mediating the response to lipopolysaccharide from Gram-negative bacteria. All TLRs have a Toll/IL-1 receptor (TIR) domain, which is responsible for signal transduction. MyD88 is one such protein that contains a TIR domain. It acts as an adapter, being involved in TLR-2, TLR-4 and TLR-9 signalling; however, our understanding of how TLR-4 signals is incomplete. Here we describe a protein, Mal (MyD88-adapter-like), which joins MyD88 as a cytoplasmic TIR-domain-containing protein in the human genome. Mal activates NF-kappaB, Jun amino-terminal kinase and extracellular signal-regulated kinase-1 and -2. Mal can form homodimers and can also form heterodimers with MyD88. Activation of NF-kappaB by Mal requires IRAK-2, but not IRAK, whereas MyD88 requires both IRAKs. Mal associates with IRAK-2 by means of its TIR domain. A dominant negative form of Mal inhibits NF-kappaB, which is activated by TLR-4 or lipopolysaccharide, but it does not inhibit NF-kappaB activation by IL-1RI or IL-18R. Mal associates with TLR-4. Mal is therefore an adapter in TLR-4 signal transduction.
-
The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signalingSchoenemeyer, Annett; Barnes, Betsy J.; Mancl, Margo E.; Latz, Eicke; Goutagny, Nadege; Pitha, Paula M.; Fitzgerald, Katherine A.; Golenbock, Douglas T. (2005-02-08)Interferon regulatory factors (IRFs) are critical components of virus-induced immune activation and type I interferon regulation. IRF3 and IRF7 are activated in response to a variety of viruses or after engagement of Toll-like receptor (TLR) 3 and TLR4 by double-stranded RNA and lipopolysaccharide, respectively. The activation of IRF5, is much more restricted. Here we show that in contrast to IRF3 and IRF7, IRF5 is not a target of the TLR3 signaling pathway but is activated by TLR7 or TLR8 signaling. We also demonstrate that MyD88, interleukin 1 receptor-associated kinase 1, and tumor necrosis factor receptor-associated factor 6 are required for the activation of IRF5 and IRF7 in the TLR7 signaling pathway. Moreover, ectopic expression of IRF5 enabled type I interferon production in response to TLR7 signaling, whereas knockdown of IRF5 by small interfering RNA reduced type I interferon induction in response to the TLR7 ligand, R-848. IRF5 and IRF7, therefore, emerge from these studies as critical mediators of TLR7 signaling.